Diagnostic dilemma: a young woman with Fabry disease symptoms, no family history, and a "sequencing cryptic" α-galactosidase a large deletion

Mol Genet Metab. 2011 Nov;104(3):314-8. doi: 10.1016/j.ymgme.2011.05.008. Epub 2011 May 14.

Abstract

Fabry disease, an X-linked lysosomal storage disorder, results from the deficient activity of α-galactosidase A (α-Gal A). In affected males, the clinical diagnosis is confirmed by the markedly decreased α-Gal A activity. However, in female heterozygotes, the α-Gal A activity can range from low to normal due to random X-chromosomal inactivation, and diagnostic confirmation requires identification of the family's α-Gal A gene mutation. In a young female who had occasional acroparesthesias, corneal opacities, and 15 to 50% of the lower limit of normal leukocyte α-Gal A activity, α-Gal A sequencing in two expert laboratories did not identify a confirmatory mutation, presenting a diagnostic dilemma. A renal biopsy proved diagnostic and renewed efforts to detect an α-Gal A mutation. Subsequent gene dosage analyses identified a large α-Gal A deletion confirming her heterozygosity, and she was started on enzyme replacement therapy. Thus, gene dosage analyses can detect large deletions (>50bp) in suspect heterozygotes for X-linked and autosomal dominant diseases that are "sequencing cryptic," resolving molecular diagnostic dilemmas.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Biopsy
  • Enzyme Replacement Therapy
  • Fabry Disease / diagnosis*
  • Fabry Disease / drug therapy
  • Fabry Disease / pathology
  • Female
  • Gene Components
  • Gene Dosage / genetics*
  • Genetic Carrier Screening / methods*
  • Humans
  • Kidney / pathology
  • Polymerase Chain Reaction
  • Sequence Analysis, DNA
  • Sequence Deletion / genetics*
  • alpha-Galactosidase / genetics*
  • alpha-Galactosidase / metabolism

Substances

  • alpha-Galactosidase